ProQR Therapeutics (PRQR) Net Income towards Common Stockholders (2021 - 2025)
Historic Net Income towards Common Stockholders for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$12.9 million.
- ProQR Therapeutics' Net Income towards Common Stockholders fell 3836.62% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year decrease of 8678.42%. This contributed to the annual value of -$30.0 million for FY2024, which is 120.94% up from last year.
- Per ProQR Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$12.9 million for Q3 2025, which was down 3836.62% from -$14.6 million recorded in Q2 2025.
- Over the past 5 years, ProQR Therapeutics' Net Income towards Common Stockholders peaked at -$2.9 million during Q2 2024, and registered a low of -$23.5 million during Q3 2022.
- In the last 5 years, ProQR Therapeutics' Net Income towards Common Stockholders had a median value of -$12.9 million in 2025 and averaged -$12.6 million.
- Per our database at Business Quant, ProQR Therapeutics' Net Income towards Common Stockholders soared by 7201.08% in 2023 and then plummeted by 40218.09% in 2025.
- Over the past 5 years, ProQR Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$20.8 million in 2021, then surged by 34.92% to -$13.6 million in 2022, then soared by 60.85% to -$5.3 million in 2023, then tumbled by 85.19% to -$9.8 million in 2024, then plummeted by 31.09% to -$12.9 million in 2025.
- Its last three reported values are -$12.9 million in Q3 2025, -$14.6 million for Q2 2025, and -$11.0 million during Q1 2025.